An observational study in Gastrointestinal Hemorrhage and Critical Illness, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Assiut University · Observational
Among 12 studies in Gastrointestinal Hemorrhage by Assiut University — 9 open to participants now, 9 under way, 1 of them phase 3. Gastrointestinal Hemorrhage · Assiut University.
Among the 12 studies in Gastrointestinal Hemorrhage by Assiut University, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2026, is one of 11 observational ones, and was the 12th registered.
338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.
Browse Gastrointestinal Hemorrhage studies →9 of the 12 studies in Gastrointestinal Hemorrhage by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18+
Assiut University · Sites in Egypt
Ages 1 days–18 yrs
Assiut University
Ages 18+
Assiut University
Ages 18+
Assiut University
Ages 18+
By country, each count listing its studies:
Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 310 is above the median of 176 across 117 observational studies indexed under Gastrointestinal Hemorrhage.
Median enrollment 100 across the 1 interventional studies, 100 across the 11 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,079 studies on the registry; 2,177 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Gastrointestinal Hemorrhage by Assiut University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07749300Phase 3Assiut UniversityTrimebutine Maleate for Enhancing Gastric Visualization in Acute Upper Gastrointestinal Bleeding | 2027-09 |
| NCT07239934Assiut UniversityPediatric GI Endoscopy at Assiut University | 2026-12-01 |
| NCT07822958Assiut UniversityGastrointestinal Bleeding in Critically Ill Patients | 2027-09-20 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies in Gastrointestinal Hemorrhage by Assiut University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective cohort study aims to determine the prevalence of gastrointestinal bleeding among critically ill patients admitted to intensive care units, identify independent risk factors, and describe clinical outcomes including ICU length of stay, transfusion requirements, and mortality at Assiut University Hospitals.
Gastrointestinal bleeding is a serious complication in critically ill patients and is associated with increased morbidity and mortality. This prospective observational cohort study will include adult patients (≥18 years) admitted to the intensive care units of Assiut University Hospitals.
Patients will be followed during their ICU stay for the occurrence of clinically important gastrointestinal bleeding (overt or occult) occurring ≥24 hours after admission. Clinical, laboratory, and treatment-related data will be collected to identify independent risk factors and to assess associated clinical outcomes.
Adult patients (≥18 years) admitted to the intensive care units of Assiut University Hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients admitted to the intensive care units who will be followed for the occurrence of ICU-acquired gastrointestinal bleeding and its associated risk factors and outcomes.
Incidence of clinically important ICU-acquired gastrointestinal bleeding
Proportion of critically ill patients who develop clinically important gastrointestinal bleeding (overt bleeding with hemodynamic compromise or significant hemoglobin drop, or occult bleeding confirmed by fecal occult blood test or endoscopy) occurring 24 hours or more after ICU admission.
Time frame: Up to 30 days
Independent risk factors for gastrointestinal bleeding
Odds ratios of clinical, laboratory, and treatment-related factors for the occurrence of clinically important gastrointestinal bleeding using multivariable logistic regression analysis.
Time frame: Up to 30 days
ICU length of stay
Duration of intensive care unit stay in days.
Time frame: Up to 30 days
Blood transfusion requirement
Number of units of packed red blood cells transfused during the ICU stay.
Time frame: Up to 30 days
ICU mortality
Proportion of patients who die during the ICU stay.
Time frame: Up to 30 days
Need for endoscopic or surgical intervention
Proportion of patients requiring endoscopic therapy or surgical intervention for gastrointestinal bleeding.
Time frame: Up to 30 days
No study locations are listed for this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 42 non-industry observational studies under Gastrointestinal Hemorrhage, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 63. This study's planned 12 months is below that.
Counting every sponsor, half of 47 studies reached it within 36 months; a quarter within 23 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.